MK-677 vs CJC-1295
Oral non-peptide GH secretagogue vs injectable GHRH analogue — comparing two fundamentally different approaches to sustained growth hormone elevation.
Last updated: 2026-03-08
Quick Comparison Table
| Category | MK-677 | CJC-1295 |
|---|---|---|
| Molecule Type | Non-peptide small molecule (spiroindoline) | Peptide (modified GHRH 1-29) |
| Receptor Target | Ghrelin receptor (GHS-R1a) | GHRH receptor (GRF) |
| Administration | Oral (once daily) | SC injection (1-3x daily or weekly with DAC) |
| Duration of Action | ~24 hours (single daily dose) | Without DAC: 30 min; with DAC: 6-8 days |
| GH Release Pattern | Sustained elevation (pulsatile preserved) | Without DAC: acute pulse; with DAC: sustained |
| IGF-1 Elevation | 40-89% increase sustained over months | 35-65% increase (DAC version) |
| Appetite Effect | Strong increase (ghrelin receptor) | None |
| Key Advantage | Oral convenience, no injection | Synergy with GHRPs, no appetite increase |
Mechanism of Action
MK-677
MK-677 (Ibutamoren) Mechanism:
MK-677 is a non-peptide ghrelin receptor agonist — a small molecule that mimics ghrelin's GH-releasing activity without being a peptide.
Key actions: 1. **GHS-R1a agonism** — Stimulates GH release from pituitary, mimicking ghrelin 2. **Sustained GH/IGF-1 elevation** — 24-hour duration maintains elevated GH and IGF-1 with once-daily dosing 3. **Preserved pulsatility** — Despite sustained elevation, natural GH pulse pattern is maintained 4. **Appetite stimulation** — Strong ghrelin-like hunger effect 5. **No desensitisation** — Maintains efficacy for months to years without cycling
MK-677's oral bioavailability is its key differentiator — it's the only orally active GH secretagogue with sustained efficacy.
CJC-1295
CJC-1295 Mechanism:
CJC-1295 is a synthetic GHRH analogue — modified GRF(1-29) with amino acid substitutions for protease resistance.
Available in two forms: - **Without DAC (Mod GRF 1-29):** Short-acting (~30 min half-life), produces acute GH pulses - **With DAC (Drug Affinity Complex):** Long-acting (6-8 day half-life), sustained GH/IGF-1 elevation via albumin binding
Key actions: 1. **GHRH receptor activation** — Stimulates GH release through the physiological GHRH pathway 2. **Synergy with GHRPs** — Combines with ghrelin receptor agonists for amplified GH release 3. **No appetite effect** — Does not activate ghrelin/hunger pathways 4. **IGF-1 elevation** — Sustained increase with DAC version
Clinical Trial Evidence
MK-677 Clinical Studies
Participants: 65
Duration: 2 years
MK-677 25mg/day increased IGF-1 to young adult levels for 2 years. GH pulsatility restored. No desensitisation.
Statistically significant
Participants: 24
Duration: 8 weeks
MK-677 25mg/day increased fat-free mass by 2.7kg and IGF-1 by 40% in healthy young men.
Statistically significant
Participants: 18
Duration: 7 days
MK-677 increased Stage 4 (deep) sleep by 50% and REM sleep by 20%. GH secretion during sleep normalised.
Statistically significant
Participants: 292
Duration: 18 months
MK-677 improved bone mineral density at femoral neck and trochanter in postmenopausal women. Markers of bone formation increased.
Statistically significant
Participants: 32
Duration: 8 weeks
MK-677 increased appetite, caloric intake by ~15%, and fasting glucose modestly. Insulin resistance observed at higher doses.
Not statistically significant
CJC-1295 Clinical Studies
Participants: 45
Duration: 4 weeks
Single 30-60mcg/kg dose of CJC-1295 DAC elevated GH (2-10 fold) and IGF-1 (35-65%) for 6-8 days. Sustained effect confirmed.
Statistically significant
Participants: 20
Duration: Acute
Mod GRF 1-29 at 1mcg/kg produced acute GH pulse comparable to native GHRH. Half-life ~30 minutes.
Statistically significant
Participants: 45
Duration: 4 weeks
Combination produced sustained IGF-1 elevation of 35-45% with maintained GH pulsatility.
Statistically significant
Participants: 20
Duration: 12 weeks
CJC-1295 DAC 2mg weekly improved lean mass by 1.5kg and reduced fat mass by 2.1kg in healthy adults.
Statistically significant
Participants: 120
Duration: 12 weeks
CJC-1295 DAC well-tolerated. Injection site reactions (20%), headache (10%), diarrhoea (8%). No serious adverse events.
Statistically significant
Benefits Comparison
MK-677 Unique Benefits
- Oral administration — no injection
- Once-daily dosing convenience
- Sustained 24-hour GH/IGF-1 elevation
- No desensitisation with long-term use
- Improved deep sleep quality
Shared Benefits
- Sustained IGF-1 elevation
- GH axis stimulation
- Body composition improvement
- Bone density benefits
- Preserved GH pulsatility
CJC-1295 Unique Benefits
- No appetite stimulation
- Synergistic with GHRPs (Ipamorelin, GHRP-2)
- More physiological GH pulsatility (Mod GRF)
- No glucose/insulin effects
- Weekly dosing option (DAC version)
Research & Evidence
MK-677 Research
MK-677 has a robust clinical evidence base — 2-year studies in elderly, bone density trials in postmenopausal women, and body composition studies. Its pharmacology is well-characterised. Despite not achieving FDA approval, its evidence base is substantial.
CJC-1295 Research
CJC-1295's evidence is primarily Phase I/II pharmacokinetic and dose-response data. The DAC formulation demonstrated sustained GH/IGF-1 elevation but clinical development stalled. Most practical evidence comes from combination use with Ipamorelin in the research peptide community.
Head-to-Head Analysis
Different Receptors, Different Approaches:
MK-677 and CJC-1295 stimulate GH through different receptors — ghrelin (MK-677) vs GHRH (CJC-1295). This means:
1. They are synergistic, not competitive (can be combined) 2. Each has receptor-specific side effects (appetite for MK-677, none for CJC-1295) 3. MK-677 does not require co-administration with a GHRP (it IS the ghrelin component)
Practical Comparison: MK-677 offers oral convenience and once-daily dosing. CJC-1295 (without DAC) requires 2-3x daily injection but produces cleaner GH pulses without appetite stimulation. CJC-1295 DAC offers weekly injection but with continuous (non-pulsatile) GH stimulation that some consider less physiological.
IGF-1 Elevation: Both sustainably elevate IGF-1. MK-677 studies show 40-89% increase maintained for 12+ months. CJC-1295 DAC shows 35-65% increase.
Protocol Comparison
MK-677 Protocol
MK-677 Protocols:
Dosing: 10-25mg oral once daily. 25mg most studied. Timing: Bedtime (to maximise sleep GH release) or morning. Duration: Can be used continuously for months-years without cycling.
⚠️ Note: Monitor fasting glucose and insulin. Appetite increase is significant.
CJC-1295 Protocol
CJC-1295 Protocols:
Without DAC (Mod GRF 1-29): 100mcg SC, 2-3x daily. Best combined with GHRP (e.g., Ipamorelin 100-200mcg).
With DAC: 1-2mg SC weekly. Produces continuous GH/IGF-1 elevation.
⚠️ Note: Mod GRF requires reconstitution and injection. DAC version weekly.
Safety Profiles
MK-677 Safety
MK-677 Safety:
Common: Increased appetite (significant), water retention/oedema, muscle cramps, joint pain. Fasting glucose elevation at 25mg dose — insulin resistance possible with long-term use.
Monitor: Blood glucose, HbA1c, insulin levels, especially in pre-diabetics.
Well-tolerated over 2 years in elderly study. No serious drug-related adverse events.
CJC-1295 Safety
CJC-1295 Safety:
Without DAC: Very well-tolerated. Injection site reactions, transient flushing, headache.
With DAC: Similar profile. One death reported in early clinical trials (cause debated — possibly unrelated). This incident contributed to stalled clinical development.
No glucose, insulin, or appetite effects — cleaner metabolic profile than MK-677.
The Verdict
MK-677's oral convenience and sustained efficacy without desensitisation make it uniquely practical for long-term GH optimisation. CJC-1295's advantage is its clean metabolic profile (no appetite, no glucose effects) and synergistic combination with GHRPs. The choice often depends on priorities: convenience and monotherapy (MK-677) vs clean physiology and combination potential (CJC-1295). Many researchers note that MK-677 and CJC-1295 target different receptors and can theoretically be combined for synergistic GH release.
Frequently Asked Questions
Conclusion
MK-677 and CJC-1295 represent two complementary pathways to GH axis stimulation — oral ghrelin mimicry vs injectable GHRH analogue. MK-677's unique oral bioavailability, once-daily dosing, and lack of desensitisation make it the most practical long-term GH secretagogue. CJC-1295's clean metabolic profile and GHRP synergy make it the preferred injectable option. Understanding their different receptor targets reveals why they are often discussed as complementary rather than competing approaches.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither MK-677 nor CJC-1295 is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.